about
Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS groupConsolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphomaImpact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.Arsenic trioxide rewires mantle cell lymphoma response to bortezomibTargeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma.Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC networkHaploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer.Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.Deletion 7q in B-cell low-grade lymphoid malignancies: a cytogenetic/fluorescence in situ hybridization and immunopathologic study.Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.Treatment of the elderly patient with mantle cell lymphoma.Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans-retinoic-acid.Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma.Identification of a leukemic counterpart of the plasmacytoid dendritic cells.Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma.Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers.Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.Severe excessive daytime sleepiness induced by hydroxyurea.R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries.Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer.Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.Clinical and biologic features of CD4+CD56+ malignanciesA phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma[Acute severe steatosis following an acute necrotic, hemorrhagic pancreatitis after treatment with asparaginase]
P50
Q31150088-ED377C9C-FDE0-499E-9A3A-9ECAF67F35D6Q33367736-846BB9E9-819A-4FC7-81FA-5FDE34736496Q33380518-08FF441A-3A1B-4A55-AF6A-391E8E9B3023Q33388563-E242C6AD-69A4-4635-AED3-2BCA7BF05995Q33437608-26FEFD19-875D-49B1-A1E8-6AB46360D102Q34255098-D64CA060-596C-42D6-AF10-55144F1C394CQ35143466-1C6A0517-9229-42D7-89BF-35B6D9555FB8Q36358595-3C9999B7-FD69-46F7-AB90-D4E48A98936CQ36649225-94D4F21E-2DC7-4D4C-B776-24F4B5EA1264Q36708985-1777DCD7-85AA-4C83-BE8D-0D47CDF5CDE0Q37299013-EB2A4FE0-60DB-4AB9-A672-0E51F5AC6ECDQ37619948-4D720AC6-5250-4661-9C68-FA76A967479CQ37621025-2510F321-77DE-44E9-BB3B-2D062CF004DDQ38500946-673E66A1-E66B-48A2-B5C2-BD69849CAE82Q39005626-A769DB9A-970C-43B7-95BA-A32AB054C080Q39027813-999CE531-19FD-4F12-8EB5-852C4EBB6EC9Q39342854-A88EC811-1E50-44D9-A90B-CD6299DD19BAQ40863791-E43CF580-71E1-43A0-8791-EF4A860C4D7FQ40902026-765C2EE2-AE0E-4E65-9514-27EB6D3C1E45Q41139081-5CFE7B17-F9AE-4134-BAD8-081820987B8EQ42926170-1B659A7F-6055-4309-8CBE-E50BB385E143Q43080849-4FCDBEC0-DAC9-457D-85CA-DFBF11E3F378Q43276971-CF87B1CC-D541-4892-916C-A782AC078307Q43600829-6275BAAC-7936-4BC5-9793-133EAD233480Q44814824-8037FE79-65E9-4BE3-9D06-61BD0985494CQ45248552-20F32645-EEC3-4241-949A-3D78DB568237Q45343242-33CA774A-B837-4B0D-BFCF-E38671AA8547Q46922494-1867B50C-0BE4-4924-9343-090CDA20CF0AQ47290596-64E94ED1-3A44-4D9F-88E2-865754FBC523Q47736956-D07B8ADF-39A2-4ABE-890E-A9717C9B9AB0Q47782098-25AEF788-6612-4A30-8927-4EFC0DBF5CEDQ48143868-FB243129-859D-43ED-8BBC-AB9CFA380F68Q48206720-B5093EA0-4387-45CA-992E-A3CC00338EAFQ51748595-9510C595-BCFB-4FD2-A1E6-C967B17D7D88Q52697946-3651CA13-600E-4297-8AEC-EA6B28168626Q52884713-EE147706-6E6D-4082-B972-1B3F5D4143FEQ53954875-FF7DEAA4-0135-4636-9BAD-91A499E21B1AQ57693402-0A09F9A8-E80E-4940-8F2A-95A78D052A74Q60922642-D1E544F8-EE92-44F8-BF19-98B86E93AC3FQ67825303-306B2DA9-F0C9-4D04-AA69-15686B515C72
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Remy Gressin
@ast
Remy Gressin
@en
Remy Gressin
@es
Remy Gressin
@nl
type
label
Remy Gressin
@ast
Remy Gressin
@en
Remy Gressin
@es
Remy Gressin
@nl
prefLabel
Remy Gressin
@ast
Remy Gressin
@en
Remy Gressin
@es
Remy Gressin
@nl
P106
P31
P496
0000-0002-9188-3501